Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Coverage also depends on the indication: the diabetes products (Ozempic, Mounjaro) and the weight products (Wegovy, Zepbound) have different coverage situations
9 The peer companies and their ratios noted in the figure include Abbvie(1.25), Amgen(1.32), AstraZeneca(0.36), Biogen(0.71), Bristol-Myers(0.86), Eli Lilly(0.43), Gilead(0.70), GSK(0.54), JNJ(0.76), Merck(0.38), Novartis(1.25), Novo Nordisk(1.41), Pfizer(0.71), Roche(0.86), and Sanofi(0.57) 10 Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
Oral semaglutide is indicated for use as an add-on combination therapy (with other glucose-lowering agents, including insulin) or as a monotherapy (in patients who are intolerant to metformin) for type 2 diabetes when diet and exercise do not provide adequate glycemic control
excursions permitted to 15C to 30C (59F to 86F)
